AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03857867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tactile Stimulation Glove
Description: A glove device produces non-painful sensory (tactile) vibratory stimulation to the fingertips of Parkinson's patients.
Study NCT02613923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: blood sample measured for stress and sleep markers
Study NCT02613923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draw
Description: blood sample measured for stress and sleep markers
Study NCT00251732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose (once daily) PPI plus low-dose antidepressant
Description: 20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
Study NCT00251732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double dose PPI plus evening placebo
Description: 20 mg. twice daily with a placebo
Study NCT02613923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.
Study NCT02613923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.
Study NCT02613923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI)
Study NCT02613923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insomnia Severity Index (ISI)
Study NCT02613923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF-12 quality of life survey
Study NCT02613923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SF-12 quality of life survey
Study NCT03958032 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention is planned for the participants for the treatment of gastric cancer. Treatment decision will be in line with clinical practice guidelines. Surgical team will be blind to the participant's sarcopenia status.
Study NCT03445871 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Blood samples will be collected for measuring PG-MTX blood concentration.
Study NCT03445871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CRQ
Description: Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
Study NCT01157312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate +highly purified uFSH
Study NCT01157312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Study NCT02350270 — intervention group
Intervention type: OTHER
Intervention: gait and cognitive testing
Study NCT04322773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RoActemra iv
Description: single dose treatment with tocilizumab 400 mg intravenously
Study NCT04322773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RoActemra sc
Description: single dose treatment with tocilizumab 2 x 162 mg subcutaneously
Study NCT04322773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kevzara sc
Description: single dose treatment with sarilumab 1 x 200 mg subcutaneously
Study NCT04322773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: management as usual
Study NCT04322773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: management as usual
Study NCT02021045 — intervention group
Intervention type: DEVICE
Intervention: Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)
Description: Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.
Study NCT01485627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication training and coaching
Description: Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
Study NCT00932347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camellia sinensis mouthwash
Description: mouthrinsing, 2 times/day, for 28 days
Study NCT00932347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: mouthrinsing, 2 times/day, for 28 days
Study NCT00354770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily
Study NCT00354770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl Cysteine
Description: 600mg capsules in varying doses for 12 weeks.
Study NCT01676675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5μg /0.5ml
Description: whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval
Study NCT01676675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15.0μg /0.5ml
Description: whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval
Study NCT01676675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30.0μg /0.5ml
Description: whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval
Study NCT01676675 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, 21 days interval
Study NCT00754832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: American ginseng extract HT-1001
Description: Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated. Subjects were then maintained on 400 mg per day or the maximum tolerated dose for the remainder of the 6 week treatment period.
Study NCT00754832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.
Study NCT01487252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: At home saliva sampling
Description: Saliva samples taken every half an hour in evening before bedtime.
Study NCT00808795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
Study NCT00808795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
Study NCT00876187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 20 mg IV
Description: 2 IV administrations of tanezumab 20 mg at an 8 week interval
Study NCT00876187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for naproxen
Description: Oral placebo for naproxen twice a day for 16 weeks
Study NCT00876187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg IV
Description: 2 IV administrations of tanezumab 10 mg at an 8 week interval
Study NCT00876187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg IV
Description: 2 IV administrations of tanezumab 5 mg at an 8 week interval
Study NCT00876187 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for tanezumab
Description: 2 IV administrations of placebo for tanezumab at an 8 week interval
Study NCT00876187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Oral naproxen 500 mg twice a day for 16 weeks
Study NCT00876187 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for tanezumab
Description: 2 IV administrations of placebo for tanezumab at an 8 week interval
Study NCT00876187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for naproxen
Description: Oral placebo for naproxen twice a day for 16 weeks
Study NCT04431570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The device is made in London, United Kingdom
Study NCT04431570 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: the device of sham stimulation was MagStim MC-P-B70 placebo butterfly coil
Study NCT01353027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT01353027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-6002
Description: Single intravenous administration
Study NCT05775185 — intervention group
Intervention type: RADIATION
Intervention: Orbital radiotherapy
Description: Low dose fractionated orbital radiotherapy, total dose 20 Gy in 2-week period.
Study NCT03096964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free walking training
Description: The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
Study NCT03096964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking training
Description: The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
Study NCT04219345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Both groups will undergo the same protocol of twelve sessions of twenty minutes of tDCS associated with mindfulness, where only the type of received electric current is varied (active or simulated sham type). The twelve sessions will be performed in three sessions per week for four weeks, and mindfulness practice at home will be encouraged on days when the intervention is not administered.
Study NCT04219345 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Both groups will undergo the same protocol of twelve sessions of twenty minutes of tDCS associated with mindfulness, where only the type of received electric current is varied (active or simulated sham type). The twelve sessions will be performed in three sessions per week for four weeks, and mindfulness practice at home will be encouraged on days when the intervention is not administered.
Study NCT03767075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg, administered IV, once every 3 weeks
Study NCT03767075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: 20 mg administered orally, once daily (QD) continuously in 28-day cycles.
Study NCT00251732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole , placebo, placebo
Description: 20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
Study NCT01352000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Approximately 3400 quitline clients will be randomized to one of three conditions at the point of their 2-week follow-up call.
Study NCT03351725 — intervention group
Intervention type: DEVICE
Intervention: peripheral venous catheter (PVC)
Description: No intervention is made only in situ swab from the PVC
Study NCT02721329 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP
Description: Automatic Continuous Positive Airway Pressure
Study NCT02721329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APAP with SensAwake
Description: Automatic Continuous Positive Airway Pressure with SensAwake enabled. SensAwake is a pressure relief technology that detects the transition from sleep to wake, and promptly reduces the pressure during wakeful periods.
Study NCT03291496 — intervention group
Intervention type: OTHER
Intervention: Blood Collection Preterm
Description: Blood will be collected on day 4 of life and then approximately every 3 days until 21 days of life. Thereafter, one sample will be collected weekly until discharge. For preterm neonates that have suspected sepsis an additional sample will be collected within 24-48 hours of the initial sepsis evaluation.
Study NCT03291496 — intervention group
Intervention type: OTHER
Intervention: Blood Collection Term
Description: A single 250 µl blood sample will be collected once the term neonate is >24 hours old.
Study NCT03291496 — intervention group
Intervention type: OTHER
Intervention: Adult Blood collection
Description: One Time 1 ml of whole blood collected
Study NCT02157883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling
Description: Blood samples taken pre and post dosing with AZD9291+/- itraconazole
Study NCT02157883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
Study NCT02157883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
Study NCT04809480 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fungal rhinosinusitis
Description: Pathology examination
Study NCT02677883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manometry-guided thoracentesis
Description: Arm I will undergo a standard of care therapeutic thoracentesis procedure, and in addition include pleural pressure monitoring (via an FDA-approved digital manometer) which is also standard of care but left at the discretion of physicians as per expert recommendations. In this group, the procedure will be stopped when the patient develops symptoms or when all the fluid has been removed, and will also be stopped if the pressure begins to fall quickly in the fluid collection.
Study NCT03767075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: 1050 mg administered IV for body weight \< 80 kg and 1400 mg for body weight >= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)
Study NCT04059770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of L-AmB
Description: (i) single IV dose of 10 mg/kg of L-AmB on day 1;
Study NCT04059770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 doses of L-AmB
Description: (ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
Study NCT04059770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 weeks of L-AmB
Description: (iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.
Study NCT03851900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teethmate Desensitizer (TM)
Description: Desensitizing agent will be applied to sensitive teeth.
Study NCT03851900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil SE Bond 2
Description: Desensitizing agent will be applied to sensitive teeth.
Study NCT03851900 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Placebo will be applied to sensitive teeth as a negative control.
Study NCT03481114 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PET-based, dose-painted, accelerated chemoradiotherapy
Description: Patients in this arm will receive a more personalized and shorter radiation therapy treatment course utilizing PET imaging.
Study NCT03481114 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemoradiotherapy
Description: Patients in this arm will receive a standard radiotherapy course.
Study NCT01032915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
Study NCT01032915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
Study NCT01032915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
Study NCT01032915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c weekly for 3 weeks then every 2 weeks
Study NCT02514915 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery
Description: Radiation therapy
Study NCT00442780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB014
Description: oral administration of BIIB014 per dose, schedule,and duration specified in protocol
Study NCT00442780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014
Study NCT01536600 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: The insulin dose and regimen was individualised at the physician's discretion
Study NCT03853785 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR vaccine
Description: Intralesional injection of 0.5 ml MMR vaccine in the largest lesion . Injections will be repeated into the same lesion every 2 weeks for a maximum of three treatment sessions.
Study NCT03853785 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Candida antigen
Description: Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by an insulin syringe in the largest wart at the first visit. Injections will be repeated for all patients into the same lesion every 2 weeks for a maximum of three treatment sessions.
Study NCT03853785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Podophyllin
Description: It will be applied to the wart by using a cotton tipped swab once a week . The procedure will be limited to 10 cm2 per session .Surrounding skin will be protected by Vaseline. Podophyllin will be washed 4 hour after application . The procedure will be repeated every week till 6 weeks .
Study NCT00892385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyamine
Description: For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.
Study NCT00892385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study NCT00142467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00142467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT00142467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00238251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib
Description: Once daily during days 1-28
Study NCT00238251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Once daily on days 1-21
Study NCT00238251 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Whole brain radiotherapy
Study NCT00913900 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous CD133+ cells
Description: Intramuscular injection
Study NCT00913900 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: autologous CD133+ cells
Description: Intramuscular injection
Study NCT03972969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facility-based structured exercise
Description: Structured exercise program in a facility with instruction and encouragement
Study NCT03972969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based structured exercise
Description: Structured exercise program in the home with instruction and encouragement
Study NCT03972969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Provision of general information about a variety of topics
Study NCT04413253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: To reduce signs and symptoms of dry eye disease
Study NCT04413253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution
Description: To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.
Study NCT03024554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the Bifurcated Multilayer Flow Modulator